**Table of Contents:**

- **AACR Annual Meeting 2013 Highlights**
- **Komen TV**
- **Komen Research Grants**
- **Fellow/ Mentor Highlight: Drs. Neil Bhola and Carlos Arteaga**
- **Grantee Alumni Highlight: Copper-Depleting Treatment Could Slow Metastasis**
- **Chronicles of Hope: Kathryn Becker**
- **Global Race for the Cure: May 11th 2013**
- **Community Connect: South Dakota**
- **Attending ASCO This Year?**
- **Komen News Updates**
- **ProFlowers Special Offer**

---

**AACR Annual Meeting 2013 Highlights**

Komen is a long-time supporter of AACR and its Annual Meeting. This year we were delighted to support four scientific sessions focused on breast cancer research, six AACR Scholars-in-Training Awards, the AACR Scientist→Survivor Program (SSP), plus 207 former and current Komen grantees presented their work at AACR!

Read more about the SSP program through a [blog](http://us4.campaignarchive2.com/?u=921a84188ebe28608151acdcb&id=fbb9cfd31b&e=) by Komen Advocate in Science member, Rebecca Seago-Coyle.

We congratulate Komen Scientific Advisory Board Member, [Dr. Carlos Arteaga](http://us4.campaignarchive2.com/?u=921a84188ebe28608151acdcb&id=fbb9cfd31b&e=), who was announced as the new President-elect for AACR!

---

**GRANT WRITING 101: "Be Organized and Clear" - Help keep your reviewers happy simply by following these 5 tips!**
In our latest episode of Komen TV, hear from our scientific leadership - the Scientific Advisory Board and Komen Scholars - about the Komen Research Program process to select grant recipients. Plus, an impassioned response from a man who shares our mission, and going to bat against breast cancer.

**Komen Research Grants**

Komen will announce the awarded 2013 Research Grants later this month. In addition, Komen anticipates releasing new Requests for Applications in Summer 2013. Check your inbox and/ or our website for an announcement of new funding opportunities.

**Fellow/ Mentor Highlight: Drs. Neil Bhola and Carlos Arteaga**

Many patients with triple negative breast cancer (TNBC) have recurrence of their disease because the cancer cells have developed a resistance to treatment. Komen Postdoctoral Fellowship Grantee, Dr. Neil Bhola and his mentor, Komen Scientific Advisory Board Member, Dr. Carlos Arteaga, recently published their findings that using TGFβ inhibitors in combination with chemotherapy may limit recurrences of treatment-resistant TNBC.

**Grantee Alumni Highlight: Copper-Depeleting Treatment Could Slow Metastasis**

Dr. Linda T. Vahdat - a 2006 Basic, Clinical, and Translational Research Grantee - recently published findings that copper-depleting treatment could slow metastasis and promote tumor dormancy in patients with a high risk for breast cancer relapse. The results of the phase 2 study, funded by Komen, were encouraging in that 2 patients with stage IV triple-negative breast cancer remain disease-free at 65 and 49 months, while the median survival rate for metastatic triple-negative patients is 9 months.
Many people know that T-DM1, now with the trade name of Kadcyla, was approved by the U.S. Food and Drug Administration (FDA) on Feb. 22, 2013 to treat HER2-positive metastatic breast cancer. Learn more about what it is like to participate on a clinical trial in the newest Chronicles of Hope piece featuring Kathryn Becker, a woman living with metastatic breast cancer whose participation helped researchers gain FDA approval for TDM-1.

Global Race for the Cure: May 11th, 2013

Make Mom Proud by joining us on Saturday, May 11, 2013, Mother’s Day weekend, for the Susan G. Komen Global Race for the Cure 5K run and walk event in the heart of Washington, D.C. The Race raises funds and awareness for the fight against breast cancer, celebrates survivorship, and honors those who have lost their battle. By showing your support for the Global Race, you’re not only honoring your own mom, but mothers and women everywhere.

Community Connect: South Dakota

Dr. Kristi Egland is South Dakota’s first Komen-funded research investigator and is developing a highly sensitive, non-invasive blood test for early diagnosis of breast cancer. As both a breast cancer survivor and a scientist who studies the disease, Dr. Egland spoke about what participating in the South Dakota Affiliate Race for the Cure means to her.

“Describing my work to other survivors inspires me to remember why I am doing this research and keeps me focused on the goal of making a difference in women’s lives. The Race allows me to promote awareness about current breast cancer research and makes me feel proud that I am a survivor.”

Attending ASCO This Year?

Komen is! Please let us know so that we can stop by your poster or presentation. We love to see our grantees in action! If you are presenting your work from a Komen-funded Grant, please remember to cite Komen’s support. Contact your Grants Administrator for more details.
Komen News Updates

• Komen Scholar, Dr. Kimberly Blackwell, was named one of Time’s 100 Most Influential People. She recently discussed using T-DM1 (Kadcyla), now FDA approved, to optimize current treatments for HER2+ metastatic breast cancer in a recent Cancer Network news article. Read our press release on T-DM1.
• Lymphoseek (T99m-Tilmanocept) is now FDA approved for sentinel lymph node mapping. Komen funded a 1999 grant to Dr. Anne Wallace of UCSD for a Phase I clinical trial that tested the safety of Lymphoseek®. Read our press release here.
• The first prototype of ASCO’s CancerLinQ was launched in March thanks to a $1M grant from Komen. Read our blog post for more details.

ProFlowers Special Offer

This Mother’s Day, don’t forget to use your special Komen discount with our Partner ProFlowers!